These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4811226)

  • 1. Inhibition of prolactin by ergoline congeners.
    Barfknecht CF; Rusterholz DB
    J Med Chem; 1974 Mar; 17(3):308-12. PubMed ID: 4811226
    [No Abstract]   [Full Text] [Related]  

  • 2. Ergoline congeners as potential inhibitors of prolactin release. 2.
    Rusterholz DB; Barfknecht CF; Clemens JA
    J Med Chem; 1976 Jan; 19(1):99-102. PubMed ID: 1246056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the concentration of adenohypophyseal prolactin and morphological manifestations in the adenohypophysis of lactating rats after administration of D-6-methyl-8-[beta-isopropylaminoethyl] ergoline-I.
    Krejcí P; Marhan O; Ausková M; Rezábek K; Semonský M
    Experientia; 1976 Oct; 32(10):1308-9. PubMed ID: 987925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the ergoline derivative VUFB-6683 on the adenohypophysial prolactin concentration in rats.
    Krejcí P; Ausková M; Rezábek K; Bílek J; Semonský M
    Experientia; 1973 Oct; 29(10):1262-3. PubMed ID: 4796640
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of ergot alkaloids on pituitary prolactin and prolactin-dependent processes.
    Floss HG; Cassady JM; Robbers JE
    J Pharm Sci; 1973 May; 62(5):699-715. PubMed ID: 4574586
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between estradiol, ergocryptine, and thyroid hormone: effects on prolactin synthesis and prolactin messenger ribonucleic acid levels.
    Maurer RA
    Endocrinology; 1982 May; 110(5):1515-20. PubMed ID: 6896178
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of ergoline derivative VUFB-6638 on the adenohypophysial prolactin concentration in rats.
    Krejcí P; Ausková M; Rezábek K; Bílek J; Semonský M
    Endocrinol Exp; 1975 Jan; 9(1):68-72. PubMed ID: 6259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ergoline congeners as potential inhibitors of prolactin release. 3. Derivatives of 3-phenylpiperidine.
    Rusterholz DB; Barfknecht CF; Clemens JA
    J Med Chem; 1977 Jan; 20(1):85-8. PubMed ID: 13217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin turnover in rat adenohypophyses in vivo: its evaluation as a method for estimating secretion rates.
    Swearingen KC; Nicoll CS
    J Endocrinol; 1972 Apr; 53(1):1-15. PubMed ID: 5021260
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopamine agonistic potency of two novel prolactin release-inhibiting ergolines.
    Markó M
    Eur J Pharmacol; 1984 Jun; 101(3-4):263-6. PubMed ID: 6468500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of norepinephrine and catecholamine-depleting agents on the synthesis and release of prolactin and growth hormone.
    MacLeod RM
    Endocrinology; 1969 Nov; 85(5):916-23. PubMed ID: 5818077
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of the growth reaction of the rat adenohypophysis to oestrogen by an ergoline derivative.
    Schreiber B; Pribýl T; Rohácová J
    Physiol Bohemoslov; 1973; 22(1):11-7. PubMed ID: 4269742
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of serum prolactin in rats by 2 ergot alkaloids and 2 ergoline derivatives: a comparison.
    Brooks CL; Welsch CW
    Proc Soc Exp Biol Med; 1974 Jul; 146(3):863-7. PubMed ID: 4841203
    [No Abstract]   [Full Text] [Related]  

  • 14. Extensive ultrastructural changes in rat mammotrophs following administration of the dopamine agonist ergocristine-reflecting inhibition of prolactin release.
    Reifel CW; Shin SH; Leather RA
    Cell Tissue Res; 1983; 232(2):249-56. PubMed ID: 6688378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microelectrophoretic identification of pituitary prolactin in Carassius auratus.
    Vodicnik MJ; McKeown BA; de Vlaming VL
    Gen Comp Endocrinol; 1978 Nov; 36(3):402-7. PubMed ID: 581757
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ergot alkaloids. Synthesis of 6-methyl-8-ergolenes as inhibitors of prolactin release.
    Li GS; Robinson JM; Floss HG; Cassady JM
    J Med Chem; 1975 Sep; 18(9):892-5. PubMed ID: 1159711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of prolactin release by the bicarbonate ion.
    Lamberts SW; MacLeod RM
    Proc Soc Exp Biol Med; 1979 Sep; 161(4):495-7. PubMed ID: 582626
    [No Abstract]   [Full Text] [Related]  

  • 19. Antihypertensive ergoline derivatives.
    Mantegani S; Temperilli A; Traquandi G; Salvati P; Di Salle E; Lamberti E; Bonsignori A
    Drug Des Deliv; 1987 May; 1(4):313-23. PubMed ID: 3509340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conformational study of phenethylamine receptor sites. 2. Synthesis of dl-2-amino-3-phenyl-trans-decalins and dl-2-isopropylamino-3-phenyl-trans-decalins.
    Smissman EE; Pazdernik TL
    J Med Chem; 1973 Jan; 16(1):18-23. PubMed ID: 4682194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.